

Geoffrey L Uy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6132474/publications.pdf>

Version: 2024-02-01

226
papers

9,299
citations

66343

42
h-index

45317

90
g-index

226
all docs

226
docs citations

226
times ranked

10691
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044.	3.5	4
2	Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. <i>Blood Advances</i> , 2022, 6, 1991-2000.	5.2	11
3	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2022, 139, 1177-1183.	1.4	41
4	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 770-773.	3.5	10
5	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabm1375.	12.4	49
6	Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. <i>Haematologica</i> , 2022, 107, 1709-1713.	3.5	2
7	Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML. <i>Blood Advances</i> , 2022, 6, 4989-4993.	5.2	7
8	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 568-583.	3.8	10
9	Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 7031-7031.	1.6	1
10	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. <i>Cancer</i> , 2021, 127, 1246-1259.	4.1	21
11	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
12	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 92-99.	1.6	13
13	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449.	1.3	2
14	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	5.2	13
15	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1474-1482.	5.2	20
16	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. <i>New England Journal of Medicine</i> , 2021, 384, 924-935.	27.0	170
17	Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. <i>Leukemia</i> , 2021, 35, 3278-3281.	7.2	10
18	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e481-e491.	4.6	92

#	ARTICLE	IF	CITATIONS
19	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7-azacytidine in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 110.	17.0	6
20	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , 2021, 5, 4691-4700.	5.2	9
21	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. <i>Leukemia Research</i> , 2021, 110, 106713.	0.8	9
22	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	3.0	4
23	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. <i>Blood</i> , 2021, 138, 800-800.	1.4	0
24	Medical Simulation in High-Risk AML Improves Clinical Decision Making of Hematologists/Oncologists. <i>Blood</i> , 2021, 138, 4985-4985.	1.4	0
25	Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	24
26	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. <i>Blood</i> , 2021, 138, 2316-2316.	1.4	0
27	Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance). <i>Blood</i> , 2021, 138, 1983-1983.	1.4	0
28	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3904-3904.	1.4	0
29	Turning AML targets inside out. <i>Blood</i> , 2021, 138, 2598-2599.	1.4	0
30	A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1156-1165.	2.6	11
31	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <i>Journal of Geriatric Oncology</i> , 2020, 11, 107-113.	1.0	38
32	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
33	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	9.4	83
34	CD123 bi-specific antibodies in development in AML: What do we know so far?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101219.	1.7	12
35	All I Really Need to Know I Learned From Pediatric Oncologists. <i>JCO Oncology Practice</i> , 2020, 16, 239-240.	2.9	0
36	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant – a retrospective study. <i>Transplant International</i> , 2020, 33, 1089-1098.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	3.5	16
38	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. <i>Investigational New Drugs</i> , 2020, 38, 1430-1441.	2.6	10
39	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , 2020, 16, e464-e475.	2.9	12
40	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	1.4	266
41	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44
42	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020, 4, 239-251.	5.2	29
43	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 16-18.	1.4	12
44	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , 2020, 136, 19-21.	1.4	5
45	Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 55-56.	1.4	2
46	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML. <i>Blood</i> , 2020, 136, 44-45.	1.4	5
47	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. <i>Blood</i> , 2020, 136, 46-48.	1.4	3
48	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. <i>Journal of Clinical Oncology</i> , 2020, 38, 7510-7510.	1.6	16
49	Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML). <i>Journal of Clinical Oncology</i> , 2020, 38, 7521-7521.	1.6	1
50	Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7567-TPS7567.	1.6	2
51	Combined Inhibition of CXCR4 Signaling and System xc- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis. <i>Blood</i> , 2020, 136, 37-37.	1.4	1
52	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123A-CD3 Bispecific DartA® Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	1.4	1
53	<i><i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i>, 2020, 136, 3-4.</i>	1.4	0
54	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). <i>Blood</i> , 2020, 136, 30-31.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 6524-6531.	7.0	12
56	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e588-e593.	0.4	6
57	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	7.2	76
58	Choosing induction chemotherapy in therapy-related acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 89-97.	1.7	3
59	CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. <i>Leukemia and Lymphoma</i> , 2019, 60, 2287-2290.	1.3	11
60	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	7.2	55
61	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq1 1 0.784314 rgBT /Over	5.2	11
62	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
63	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2019, 134, 733-733.	1.4	14
64	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degradator, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. <i>Blood</i> , 2019, 134, 232-232.	1.4	17
65	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2019, 134, 2547-2547.	1.4	5
66	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 15-15.	1.4	27
67	CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2630-2630.	1.4	4
68	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2019, 134, 5144-5144.	1.4	4
69	Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2019, 134, 1366-1366.	1.4	2
70	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. <i>Blood</i> , 2019, 134, 3915-3915.	1.4	6
71	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 414-423.	4.9	44
72	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic MicRNAs (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2019, 134, 2694-2694.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2650-2650.	1.4	1
74	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). <i>Blood</i> , 2019, 134, 1247-1247.	1.4	1
75	CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. <i>Blood</i> , 2019, 134, 2745-2745.	1.4	1
76	Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation. <i>Thorax</i> , 2018, 73, 489-492.	5.6	12
77	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
78	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	1.6	682
79	A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. <i>Blood Advances</i> , 2018, 2, 1295-1299.	5.2	25
80	Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 417-425.	2.3	64
81	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 1028-1041.	27.0	93
82	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	6.4	72
83	Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
84	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E49-E52.	4.1	14
85	Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with <i>IDH1</i> -Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2018, 132, 561-561.	1.4	30
86	Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study. <i>Blood</i> , 2018, 132, 1425-1425.	1.4	8
87	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. <i>Blood</i> , 2018, 132, 2706-2706.	1.4	1
88	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart [®] Molecule for T-Cell Redirected Therapy. <i>Blood</i> , 2018, 132, 2738-2738.	1.4	9
89	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701. <i>Blood</i> , 2018, 132, 309-309.	1.4	14
90	Ivosidenib (IVO; AG-120) in mutant <i>IDH1</i> relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7000-7000.	1.6	3

#	ARTICLE	IF	CITATIONS
91	CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.. Journal of Clinical Oncology, 2018, 36, 7027-7027.	1.6	3
92	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 2018, 9, 4354-4365.	1.8	16
93	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology, 2018, 36, 7040-7040.	1.6	0
94	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. Journal of Clinical Oncology, 2018, 36, 7031-7031.	1.6	2
95	Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2018, 132, 89-89.	1.4	9
96	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). Blood, 2018, 132, 1386-1386.	1.4	4
97	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	1.4	0
98	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
99	The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models. Blood, 2018, 132, 2700-2700.	1.4	3
100	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). Blood, 2018, 132, 2767-2767.	1.4	0
101	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. Blood, 2018, 132, 118-118.	1.4	2
102	T Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653.	2.0	38
103	A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer Journal, 2017, 7, e542-e542.	6.2	41
104	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
105	Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood, 2017, 129, 1397-1401.	1.4	24
106	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Biology of Blood and Marrow Transplantation, 2017, 23, 1282-1289.	2.0	5
107	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 2017, 102, 1391-1400.	3.5	28
108	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood, 2017, 129, 2680-2692.	1.4	66

#	ARTICLE	IF	CITATIONS
109	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1072-1077.	2.0	39
110	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	4.9	67
111	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , 2017, 6, 2814-2821.	2.8	21
112	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2065-2069.	2.0	19
113	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12629.	1.7	75
114	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. <i>Leukemia</i> , 2017, 31, 872-881.	7.2	87
115	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017, 1, 331-340.	5.2	57
116	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2017, 130, 637-637.	1.4	49
117	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2017, 130, 725-725.	1.4	14
118	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , 2017, 130, 816-816.	1.4	7
119	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> , 2016, 1, 250-259.	5.2	142
120	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
121	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	3.5	54
122	Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1324-1329.	2.0	35
123	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2535-2540.	1.3	11
124	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.8	31
125	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663
126	Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. <i>Blood</i> , 2016, 127, 122-131.	1.4	148

#	ARTICLE	IF	CITATIONS
127	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1851-1860.	2.0	135
128	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
129	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 728-730.	1.3	14
130	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. <i>Blood</i> , 2016, 128, 1070-1070.	1.4	28
131	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2745-2745.	1.4	3
132	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance). <i>Blood</i> , 2016, 128, 2782-2782.	1.4	7
133	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. <i>Journal of Clinical Oncology</i> , 2016, 34, 7000-7000.	1.6	130
134	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. <i>Blood</i> , 2016, 128, 4658-4658.	1.4	0
135	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. <i>Blood</i> , 2015, 126, 2484-2490.	1.4	207
136	Acute Lymphoblastic Leukemia, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1240-1279.	4.9	116
137	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. <i>Bone Marrow Transplantation</i> , 2015, 50, 1057-1062.	2.4	23
138	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1425-1430.	2.0	12
139	Targeting the Microenvironment in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 126-131.	2.3	68
140	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1513-1518.	2.4	34
141	Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2015, 39, 1437-1442.	0.8	11
142	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
143	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1686-1686.	1.4	1
144	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , 2015, 126, 1950-1950.	1.4	5

#	ARTICLE	IF	CITATIONS
145	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2546-2546.	1.4	15
146	Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale. <i>Blood</i> , 2015, 126, 2793-2793.	1.4	5
147	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3098-3098.	1.4	1
148	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). <i>Blood</i> , 2015, 126, 319-319.	1.4	18
149	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. <i>Blood</i> , 2015, 126, 610-610.	1.4	3
150	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015, 126, 689-689.	1.4	1
151	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015, 126, 796-796.	1.4	12
152	CXCR4/CXCL12 as a Therapeutic Target. , 2015, , 607-615.		0
153	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3144-3144.	1.4	0
154	Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1. <i>Blood</i> , 2015, 126, 5170-5170.	1.4	0
155	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. <i>Blood</i> , 2015, 126, 3106-3106.	1.4	0
156	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1366-1370.	2.4	6
157	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. <i>International Journal of Hematology</i> , 2014, 99, 272-278.	1.6	32
158	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 46-52.	2.0	86
159	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 487-492.	4.1	9
160	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. <i>American Journal of Hematology</i> , 2014, 89, E103-8.	4.1	15
161	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. <i>Bone Marrow Transplantation</i> , 2014, 49, 1124-1126.	2.4	24
162	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33

#	ARTICLE	IF	CITATIONS
163	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , 2014, 124, 2447-2447.	1.4	1
164	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2557-2557.	1.4	1
165	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). <i>Blood</i> , 2014, 124, 8-8.	1.4	31
166	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , 2014, 124, 1931-1931.	1.4	4
167	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	1.4	1
168	G-CSF Augments Inotuzamab-Mediated Clearance of Acute Lymphoblastic Leukemia from the Bone Marrow. <i>Blood</i> , 2014, 124, 5502-5502.	1.4	0
169	Impact of Remission Status on Outcomes in AML Patients ≥ 60 Years of Age after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1263-1263.	1.4	0
170	Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. <i>Blood</i> , 2014, 124, 3944-3944.	1.4	0
171	Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation. <i>Blood</i> , 2014, 124, 906-906.	1.4	1
172	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5292-5292.	1.4	0
173	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	1.4	0
174	A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. <i>Leukemia</i> , 2013, 27, 725-728.	7.2	38
175	Dual Receptor T Cells Mediate Pathologic Alloreactivity in Patients with Acute Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 188ra74.	12.4	29
176	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , 2013, 122, 2653-2653.	1.4	3
177	Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®). <i>Blood</i> , 2013, 122, 360-360.	1.4	14
178	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5492-5492.	1.4	3
179	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. <i>Blood</i> , 2013, 122, 3931-3931.	1.4	0
180	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. <i>Blood</i> , 2013, 122, 2816-2816.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1398-1398.	1.4	0
182	Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies. <i>Blood</i> , 2013, 122, 2034-2034.	1.4	1
183	Plasmacytoma-Like Post-Transplantation Lymphoproliferative Disease Occurring in a Cardiac Allograft: A Case Report and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2012, 30, e278-e282.	1.6	8
184	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2012, 119, 3917-3924.	1.4	347
185	Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctgsg-PML-RARA Mice. <i>PLoS ONE</i> , 2012, 7, e46529.	2.5	15
186	Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04â€0274) and review of the literature. <i>Transplant Infectious Disease</i> , 2012, 14, 259-267.	1.7	23
187	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92
188	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1828-1833.	1.4	104
189	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. <i>Journal of Clinical Investigation</i> , 2011, 121, 1445-1455.	8.2	91
190	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. <i>Blood</i> , 2011, 118, 82-82.	1.4	16
191	Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3633-3633.	1.4	0
192	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3616-3616.	1.4	1
193	Phase I Study of Cladribine (2-chlorodeoxyadenosine), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. <i>Blood</i> , 2011, 118, 3609-3609.	1.4	0
194	A protease-resistant PML-RARÎ± has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. <i>Blood</i> , 2010, 116, 3604-3610.	1.4	12
195	Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. <i>Leukemia</i> , 2010, 24, 1662-1664.	7.2	27
196	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. <i>Blood</i> , 2010, 116, 1060-1060.	1.4	10
197	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. <i>Blood</i> , 2010, 116, 1063-1063.	1.4	1
198	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Blood</i> , 2010, 116, 823-823.	1.4	1

#	ARTICLE	IF	CITATIONS
199	A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2009, 84, 560-564.	4.1	51
200	Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. <i>American Journal of Hematology</i> , 2009, 84, 733-737.	4.1	42
201	Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. <i>Oncology Reviews</i> , 2009, 3, 59-70.	1.8	0
202	Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. <i>Bone Marrow Transplantation</i> , 2009, 43, 793-800.	2.4	26
203	Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. <i>Bone Marrow Transplantation</i> , 2009, 44, 13-17.	2.4	19
204	Plerixafor. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 105-107.	46.4	97
205	BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. <i>Blood</i> , 2009, 114, 1340-1343.	1.4	153
206	Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2009, 50, 14-23.	1.3	12
207	Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. <i>Blood</i> , 2009, 113, 6206-6214.	1.4	456
208	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3417-3417.	1.4	1
209	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. <i>Blood</i> , 2009, 114, 787-787.	1.4	5
210	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , 2009, 114, 842-842.	1.4	4
211	Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. <i>Blood</i> , 2009, 114, 3335-3335.	1.4	0
212	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056.	2.0	319
213	Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1797-1804.	3.1	92
214	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. <i>Blood</i> , 2008, 112, 1944-1944.	1.4	8
215	Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients > 60 years old. <i>Journal of Clinical Oncology</i> , 2008, 26, 7058-7058.	1.6	1
216	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/ML or >5,000 Copies/ML X 2. <i>Blood</i> , 2008, 112, 4340-4340.	1.4	0

#	ARTICLE	IF	CITATIONS
217	A Protease-Resistant PML-RAR α ± Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL).. Blood, 2008, 112, 930-930.	1.4	0
218	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. Blood, 2008, 112, 4427-4427.	1.4	0
219	Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 587-589.	1.4	32
220	FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. Blood, 2007, 110, 1855-1855.	1.4	1
221	Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.. Blood, 2007, 110, 867-867.	1.4	4
222	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. Blood, 2007, 110, 916-916.	1.4	8
223	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. Blood, 2007, 110, 1451-1451.	1.4	1
224	Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.. Blood, 2007, 110, 1203-1203.	1.4	1
225	Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene, 2001, 20, 1839-1851.	5.9	181
226	Exhaled nitric oxide correlates with experimental lung transplant rejection. Annals of Thoracic Surgery, 2000, 69, 210-215.	1.3	12